Novavax Inc. Stock Underperforms Wednesday When Compared To Competitors

Tricida Inc

Change company Symbol lookup

Select an option...

TCDAQ Tricida Inc

HROWL HARROW HEALTH 8 625 SNR NTS

MLTX MoonLake Immunotherapeutics

TRTN Triton International Ltd

PAYA Paya Holdings Inc

MA Mastercard Inc

MWRK MetaWorks Platforms Inc

NSRGY Nestle SA

MIN MFS? Intermediate Income Fund

MCO Moody's Corp

Health Care : Pharmaceuticals | Small Cap Value

Company profile

Tricida, Inc. is a pharmaceutical company, which is focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101). TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The Company's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.

Novavax Inc. Stock Underperforms Wednesday When Compared To Competitors

5:13 pm ET November 16, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) slid 7.54% to $21.47 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 1.54% to 11,183.66 and Dow Jones Industrial Average falling 0.12% to 33,553.83. Novavax Inc. closed $215.03 short of its 52-week high ($236.50), which the company achieved on December 20th.

The stock underperformed when compared to some of its competitors Wednesday, as Replimune Group Inc. (REPL) fell 2.39% to $19.22, VBI Vaccines Inc. (VBIV) fell 6.91% to $0.64, and AnaptysBio Inc. (ANAB) fell 5.31% to $28.37. Trading volume (3.8 M) remained 1.4 million below its 50-day average volume of 5.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 16, 2022.

(END) Dow Jones Newswires

November 16, 2022 17:13 ET (22:13 GMT)